DLL3-expressing Tumors
2 clinical trials · Condition
◉ Watch DLL3-expressing Tumors
| Record | Firm | Date |
|---|---|---|
| DLL3-Targeted PET/CT in Neuroendocrine Carcinoma (NCT07458906) | The First Affiliated Hospital of Xiamen University | 2025-12-01 |
| Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms (NCT06788938) | Jonsson Comprehensive Cancer Center | 2025-03-21 |
Track DLL3-expressing Tumors automatically
Every clearance here is in the API, with alerts when new ones post.